2026-03-10 05:17:26
Brigatinib as a targeted therapy demonstrates significant efficacy in treating Neurofibromatosis Type 2 (NF2), capable of reducing tumor volume and improving hearing function, providing new hope for patients unable to benefit from surgery or radiation.
2025-10-19 11:44:20
2025-10-19 11:44:20